As federal courts weigh the future of mifepristone access, some clinicians are preparing for a scenario many hoped was behind them: relying on misoprostol-only regimens for both abortion and early pregnancy loss care. A recent ruling from the U.S. Court of Appeals for the Fifth Circuit would reinstate in-person dispensing requirements for mifepristone, which would curtail telehealth prescribing and mail distribution.